Silo Pharma, Inc.
SILO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001514183
No open-market purchases or sales by Silo Pharma, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $886.6K in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Silo Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- +3 vs. Q3 2024
- Shares held
- 190.8K
- −158.6K (−45.4%) vs. Q3 2024
- Total value
- $168.4K
- −$214.9K (−56.1%) vs. Q3 2024
- New holders
- 5
- 2 more added
- Sold out
- 2
- 4 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SILO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $886.6K |
| Q1 2026 | 15 | $379.8K |
| Q4 2025 | 15 | $412.4K |
| Q3 2025 | 14 | $1.07M |
| Q2 2025 | 13 | $256.3K |
| Q1 2025 | 13 | $285.0K |
| Q4 2024 | 16 | $168.4K |
| Q3 2024 | 13 | $383.3K |
| Q2 2024 | 10 | $117.9K |
| Q1 2024 | 11 | $1.22M |
| Q4 2023 | 10 | $231.3K |
| Q3 2023 | 8 | $175.7K |
| Q2 2023 | 7 | $203.6K |
| Q1 2023 | 6 | $183.3K |
| Q4 2022 | 8 | $72.3K |
| Q3 2022 | 4 | $273.0K |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Silo Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Renaissance Technologies LLC | 37,500 | $33.4K | 0.00% | −189,506−83.5% | Reduced |
| Geode Capital Management, LLC | 34,948 | $31.1K | 0.00% | +4,187+13.6% | Added |
| UBS Group AG | 20,085 | $17.9K | 0.00% | +20,085 | New |
| Vanguard Group Inc | 16,334 | $14.5K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 14,563 | $13.0K | 0.00% | +14,563 | New |
| State Street Corp | 12,500 | $11.1K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 11,375 | $10.1K | 0.00% | +11,375 | New |
| HRT Financial LP | 11,448 | $10.0K | 0.00% | +11,448 | New |
| Virtu Financial LLC | 10,430 | $9.00K | 0.00% | −15,185−59.3% | Reduced |
| Bullock Wealth Management Group | 7,246 | $6.45K | 0.00% | −4,347−37.5% | Reduced |
| Federation des caisses Desjardins du Quebec | 6,000 | $5.34K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 4,547 | $4.05K | 0.00% | +486+12.0% | Added |
| Citigroup Inc | 2,691 | $2.40K | 0.00% | +2,691 | New |
| Westside Investment Management, Inc. | 94 | $84 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 36 | $32 | 0.00% | 00.0% | Unchanged |
| Lazard Asset Management LLC | 953 | $0 | 0.00% | −65−6.4% | Reduced |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −14,373−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −1−100.0% | Sold out |